Relay Therapeutics (RLAY) director granted options on 32,947 shares

Rhea-AI Filing Summary

Relay Therapeutics director Linda A. Hill received a stock option grant covering 32,947 shares of common stock. The option has an exercise price of $14.09 per share and was granted as a compensation award, not an open-market purchase or sale.

The option was granted on June 9, 2026 and vests in full on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following that date. The option expires on June 8, 2036 if not exercised.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider HILL LINDA A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	32,947	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 32,947 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 32,947 shares Exercise price: $14.09 per share Expiration date: June 8, 2036 +2 more

5 metrics

Option grant size 32,947 shares Stock option covering common stock granted June 9, 2026

Exercise price $14.09 per share Stock option exercise price for 32,947 shares

Expiration date June 8, 2036 Option term end date if not exercised

Vesting trigger 1 year or next annual meeting Vests on earlier of first anniversary or next annual stockholder meeting

Post-grant derivative holdings 32,947 options Total derivative securities following this transaction

Key Terms

Stock Option (Right to Buy), grant/award acquisition, exercise price, vests in full, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

exercise price financial

"conversion_or_exercise_price: 14.0900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in full financial

"option was granted ... and vests in full on the earlier to occur"

annual meeting of stockholders financial

"the date of the next annual meeting of stockholders following the grant date"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HILL LINDA A

(Last) (First) (Middle)

C/O RELAY THERAPEUTICS, INC.

60 HAMPSHIRE STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Relay Therapeutics, Inc. [ RLAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.09	06/09/2026		A		32,947		(1)	06/08/2036	Common Stock	32,947	$0	32,947	D

Explanation of Responses:

1. This option was granted on June 9, 2026 with respect to 32,947 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

	/s/ Soo-Yeun Lim, as Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Relay Therapeutics (RLAY) report for Linda A. Hill?

Relay Therapeutics reported a grant of stock options to director Linda A. Hill. She received options for 32,947 shares of common stock as a compensation award, not an open-market trade, under a standard equity incentive structure.

How many Relay Therapeutics (RLAY) shares are covered by Linda A. Hill’s new options?

The new stock option grant to Linda A. Hill covers 32,947 shares of Relay Therapeutics common stock. These options give her the right to buy that number of shares if they vest and she chooses to exercise them before expiration.

What is the exercise price of Linda A. Hill’s Relay Therapeutics (RLAY) stock options?

The stock options granted to Linda A. Hill have an exercise price of $14.09 per share. This is the price she would pay per share if she exercises the options once they are vested and before they expire in 2036.

When do Linda A. Hill’s Relay Therapeutics (RLAY) stock options vest?

The options vest in full on the earlier of the first anniversary of the June 9, 2026 grant date or the date of the next annual meeting of stockholders. This structure ties vesting to director service or the upcoming annual meeting.

When do Linda A. Hill’s Relay Therapeutics (RLAY) stock options expire?

The stock options granted to Linda A. Hill expire on June 8, 2036. She can choose to exercise any vested portion before that date at the $14.09 per share exercise price, subject to the company’s equity plan rules.

Is Linda A. Hill’s Relay Therapeutics (RLAY) Form 4 transaction a stock purchase or sale?

The Form 4 reports a grant of stock options, not a purchase or sale of common shares in the market. It is classified as a grant or award acquisition, reflecting equity-based compensation for her role as a director.